FlowMedica: Making Renal Failure Real

For a selelct group of patients undergoing interventional procedures or cardiac surgery, the risk of acute renal failure, caused by the body's inability to flush out high doses of contrast agents, represents a major, and potentially life-threatening complication. FlowMedica hopes to make prevention and treatment of acute renal failure a standard of care with an innovative technology that links drug and device therapies.

By David Cassak

Over the past decade or so, the clinical imperialism—if that's not too strong a word—of interventional cardiology has been nothing...

More from Archive

More from In Vivo

Podcast: ADDF’s Karen Harris On Investing In Alzheimer’s Like A VC

 
• By 

A discussion with Karen Harris, CFO of the Alzheimer's Drug Discovery Foundation, about the foundation's investment strategy, biotech and investor sentiment at the recent BIO conference and what innovations give her hope for Alzheimer's patients.

Turning Defense Into Attack: Snapshots Of A Changing Medtech Market And How To Respond

 
• By 

Against a backdrop of shifting trade policies, the end of multilateral market approaches and renewed focus on supply chain resilience, medtechs are doubling down on innovation in products and processes – using AI – and keeping unmet needs and outcomes in the center of the target.

AI Agents Set To Reshape Biopharma’s Workforce And Operations

 
• By 

While biopharma companies experiment with genAI, agentic AI is rapidly shifting the work paradigm towards one of autonomous digital workers that can handle entire process flows.